Arrakis Therapeutics
35 Gatehouse Drive
Waltham
Massachusetts
02451
United States
Website: http://arrakistx.com/
Email: info@arrakistx.com
About Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines. Our goal is to interrogate and exploit the vast and largely unexplored transcriptome—the full collection of RNAs transcribed from DNA—to discover small-molecule medicines that target RNA at key disease intervention points.YEAR FOUNDED:
2015
LEADERSHIP:
Founder: Raj Parekh, Ph.D.
Founder and CSO: Russell C. Petter, Ph.D.
CEO and Chairman: Michael Gilman, Ph.D.
CBO: Daniel Koerwer
Senior VP, Biology: James Barsoum, Ph.D.
CAREER:
Please click here for Arrakis Therapeutics' job opportunities.
29 articles about Arrakis Therapeutics
-
Arrakis Therapeutics to Present at Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 3:30 p.m. ET in New York.
-
Arrakis Therapeutics to Participate in Upcoming May 2022 Investor Conferences
5/10/2022
Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: 2022 RBC Capital Markets Global Healthcare Conference Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a fireside chat on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York.
-
Arrakis Therapeutics to Participate in Upcoming Investor Conferences - Mar 31, 2022
3/31/2022
Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a panel discussion on Thursday, April 7, 2022 at 11:00 a.m.
-
Arrakis Therapeutics to Present at Guggenheim Healthcare Talks Oncology Conference
2/8/2022
Arrakis Therapeutics today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Guggenheim Healthcare Talks Oncology Conference on Friday, February 11, 2022 at 10:00 a.m. ET.
-
Despite the massive financing from venture capitalists that poured into Massachusetts in 2021, Bay State biopharma companies are struggling to find enough talent to fill the number of available jobs.
-
BioSpace takes a look at the presentations made by Amgen, GSK and 2sevent bio at the all-virtual J.P. Morgan Conference.
-
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS
1/11/2022
Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.
-
Amgen will partner with Arrakis Therapeutics for an innovative collaboration to research and develop RNA degrader therapeutics.
-
Arrakis Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
1/10/2022
Arrakis Therapeutics today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 8:30 a.m. ET.
-
Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer
12/6/2021
Arrakis Therapeutics today announced that James Mutamba, PhD, has joined the company as Chief Business Officer.
-
Arrakis Therapeutics Announces New Scientific Advisory Board Members
3/23/2021
Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, announced today that it has appointed Amanda E. Hargrove, Ph.D., and Adrian Whitty, Ph.D., to its Scientific Advisory Board.
-
Arrakis Therapeutics Appoints Patrizio Renzetti as Vice President of Human Resources
11/19/2020
Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Patrizio Renzetti has joined the company as Vice President, Human Resources. Patrizio is an experienced human resources leader with broad expertise at dynamic high-growth companies, both large and small, including Agios Pharmaceuticals, Lilly, and Procter &a
-
Arrakis Therapeutics Publishes Advanced Research Method To Systematically Identify RNA-Targeted Small Molecules
8/31/2020
Technology platform tool, PEARL-seq™, identifies binding sites in RNA by integrating proprietary bioinformatics workflow with chemical biology techniques for the rational design of rSM therapeutics WALTHAM, Mass.--( BUSINESS WIRE )-- Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced the publication of data demonstrating the capabilities
-
Arrakis Therapeutics Appoints Erik Spek, Ph.D., J.D., as Vice President, Legal and Intellectual Property
7/15/2020
Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Erik Spek, Ph.D., J.D., has joined the company as Vice President, Legal and Intellectual Property. Dr. Spek is an experienced biotech executive who has been a leader in corporate legal affairs and intellectual property for biotech companies, including Vedant
-
Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform
4/8/2020
Arrakis Receives $190 Million Upfront Cash Payment with Potential for Multi-Billion Dollar Future Payments
-
“We are excited to partner with Roche’s strong research and development team,” said Michael Gilman, Arrakis’ chief executive officer.
-
Arrakis Therapeutics Appoints Jacques Dumas, Ph.D., as Senior Vice President, Drug Discovery
2/5/2020
Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Jacques Dumas, Ph.D., has joined the company as Senior Vice President, Drug Discovery.
-
As the J.P. Morgan Healthcare Conference winds down for 2020, one of the big topics was the general lack of big deals. Still, there were some general trends and for today, some news.
-
BioSpace Movers & Shakers, Nov. 22
11/22/2019
Pharma and biotech companies strengthen their leadership teams and boards with this week's appointments. -
Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors
11/21/2019
Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, announced today that it has appointed Katrine Bosley as Chairman of its Board of Directors